Presbyopia is an eye disorder, in which one’s eyes gradually lose the ability to see things clearly up close distances. It is a normal part of aging. In addition, myopia is a common eye disorder that cause vision loss, and uncorrected myopia is amongst the leading cause of distance vision impairment worldwide. Several individual studies have shown variations in the prevalence of high myopia and myopia in regions and ethnic groups, and there continues to be uncertainty regarding increasing prevalence of myopia. Moreover, market players are focused on inorganic strategies such as partnerships, in order to increase awareness about childhood myopia which in turn is expected to boost the market growth over the forecast period. For instance, in October 2020, Myopia Profile Pty Ltd and Essilor International entered into a partnership agreement for empowering eye care practitioners with skills, clinical knowledge, and practice in managing childhood myopia. The partnership will also boost public awareness of the consequences of myopia, also called near sightedness, and in addition, this will also encourage parents to have their children’s vision tested.
Market Dynamics
Researchers are focusing on research and development activities for the development of new treatment for myopia and presbyopia, by using new technologies, which is expected to drive growth of the global myopia & presbyopia eye drops market over the forecast period. For instance, in January 2019, Bar-Ilan University’s Institute of Nanotechnology and Advanced Materials (BINA), Israel, developed eye drops called as ‘nanodrops’ for correcting the refractive-related vision problems such as myopia and presbyopia. The eye drops are made up of a synthetic nanoparticle solution and have been tested on pig’s cornea. The researchers reported that the drops treated two kinds of refractive errors: myopia and presbyopia in pigs.
Key features of the study:
- This report provides an in-depth analysis of the global myopia & presbyopia eye drops market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global myopia & presbyopia eye drops market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, strategies
- Key companies covered as a part of this study include Orasis Pharmaceuticals, AbbVie Inc. (Allergan), Novartis AG, OSRX Pharmaceuticals, LENZ Therapeutics, Visus Therapeutics, Ocuphire Pharma Inc., Eyenovia, Inc., Vyluma Inc., and Jawa Pharmaceuticals (India) Pvt. Ltd.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global myopia & presbyopia eye drops market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have an ease in decision-making through various strategy matrices used in analyzing the global myopia & presbyopia eye drops market
Detailed Segmentation:
- Global Myopia & Presbyopia Eye Drops Market, By Eye Drops:
- Atropine Drops
- Pipeline Products
- CSF-1
- AGN – 190584
- Nyxol
- UNR844-Cl
- PRX-100
- MicroLine
- Others
- Global Myopia & Presbyopia Eye Drops Market, By Indication:
- Global Myopia & Presbyopia Eye Drops Market, By End User:
- Hospitals
- Ophthalmic Clinics
- Others
- Global Myopia & Presbyopia Eye Drops Market, By Region:
- North America
- By Eye Drops
- Atropine Drops
- Pipeline Products
- CSF-1
- AGN – 190584
- Nyxol
- UNR844-Cl
- PRX-100
- MicroLine
- Others
- By Indication
- By End User
- Hospitals
- Ophthalmic Clinics
- Others
- By Country
- Latin America
- By Eye Drops
- Atropine Drops
- Pipeline Products
- CSF-1
- AGN – 190584
- Nyxol
- UNR844-Cl
- PRX-100
- MicroLine
- Others
- By Indication
- By End User
- Hospitals
- Ophthalmic Clinics
- Others
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Eye Drops
- Atropine Drops
- Pipeline Products
- CSF-1
- AGN – 190584
- Nyxol
- UNR844-Cl
- PRX-100
- MicroLine
- Others
- By Indication
- By End User
- Hospitals
- Ophthalmic Clinics
- Others
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Eye Drops
- Atropine Drops
- Pipeline Products
- CSF-1
- AGN – 190584
- Nyxol
- UNR844-Cl
- PRX-100
- MicroLine
- Others
- By Indication
- By End User
- Hospitals
- Ophthalmic Clinics
- Others
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Eye Drops
- Atropine Drops
- Pipeline Products
- CSF-1
- AGN – 190584
- Nyxol
- UNR844-Cl
- PRX-100
- MicroLine
- Others
- By Indication
- By End User
- Hospitals
- Ophthalmic Clinics
- Others
- By Country
- GCC
- Israel
- Rest of Middle East
- Africa
- By Eye Drops
- Atropine Drops
- Pipeline Products
- CSF-1
- AGN – 190584
- Nyxol
- UNR844-Cl
- PRX-100
- MicroLine
- Others
- By Indication
- By End User
- Hospitals
- Ophthalmic Clinics
- Others
- By Country/Region
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Orasis Pharmaceuticals*
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- AbbVie Inc. (Allergan)
- Novartis AG
- OSRX Pharmaceuticals
- LENZ Therapeutics
- Visus Therapeutics
- Ocuphire Pharma Inc.
- Eyenovia, Inc.
- Vyluma Inc.
- Jawa Pharmaceuticals (India) Pvt. Ltd.
“*” marked represents similar segmentation in other categories in the respective section.
